title: Detection of CK20mRNA in peripheral blood of pancreatic cancer and its clinical significance.
abstract: OBJECTIVE
  To detect the expression of CK20mRNA in peripheral blood of pancreatic cancer and evaluate its clinical significance.
  
  
  METHODS
  Expression of CK20mRNA in peripheral blood was detected by fluorogenic qualitative reverse transcription-polymerase chain reaction (RT-PCR) in 40 cases of pancreatic cancer at the night before operation, in 5 cases of benign pancreatic diseases, in 5 cases of healthy individuals. The relationships were investigated between CK20mRNA expression and the clinicopathological variables, and clinical follow-up outcome in those patients with pancreatic cancer having undergone radical resection.
  
  
  RESULTS
  Of the 40 patients with pancreatic cancer, 23 (57.5%) cases were positive for CK20mRNA expression. CK20mRNA expression was significantly correlated with lymphatic metastasis (P = 0.008), histopathological grading (P = 0.009), and pathological stage (P = 0.021); there was no significant correlation between CK20mRNA expression and age, gender, tumor diameter, and depth of invasion. The cumulative metastasis rates of patients with CK20mRNA expression were higher than those of patients with no CK20mRNA expression within 6 mo (34.7% vs 5.9%, P = 0.043) or 12 mo (73.9% vs 35.3%, P = 0.02) after operation. CK20mRNA expression in peripheral blood of pancreatic cancer indicated poorer prognosis. The survival rate of patients with CK20mRNA expression was lower than that of patients with negative CK20mRNA expression (Log-Rank = 13.31, P = 0.0003).
  
  
  CONCLUSIONS
  CK20mRNA is a sensitive and specific molecular marker for the detection of micrometastasis in peripheral blood of patients with pancreatic cancer. The CK20mRNA expression in peripheral blood is correlated with biological characteristic of pancreatic cancer. It can help to predict the prognosis of pancreatic cancer after operation, and to determine which patient will benefit from aggressive adjuvant therapies.
authors.affiliation: Department of Hepato-Pancreatico-Billiary Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China. zylzrl@mail.hz.zj.cn
authors.forename: Yun-Li
authors.initials: YL
authors.lastname: Zhang
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Feng
authors.forename: Jian-Min
authors.initials: JM
authors.lastname: Gou
authors.forename: Li-Xin
authors.initials: LX
authors.lastname: Zhou
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007381:Intermediate Filament Proteins / Q000235:genetics*; D053554:Keratin-20; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D011379:Prognosis; D012333:RNA, Messenger / Q000097:blood; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D007381:Intermediate Filament Proteins; C507499:KRT20 protein, human; D053554:Keratin-20; D012333:RNA, Messenger
references.citation: J Virol Methods. 2004 Aug;119(2):145-50
references.pmid: 15158596
references.citation: Surgery. 2003 Dec;134(6):964-71; discussion 971-2
references.pmid: 14668729
references.citation: J Cancer Res Clin Oncol. 2003 Mar;129(3):192-8
references.pmid: 12684893
references.citation: Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):332-8
references.pmid: 12613443
references.citation: Ann Surg. 2003 Jan;237(1):74-85
references.pmid: 12496533
references.citation: CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
references.pmid: 12568441
references.citation: J Virol Methods. 2002 Sep;105(2):253-63
references.pmid: 12270658
references.citation: Mod Pathol. 2003 May;16(5):403-10
references.pmid: 12748245
references.citation: Anal Biochem. 2003 Apr 1;315(1):95-105
references.pmid: 12672417
references.citation: World J Gastroenterol. 2003 Aug;9(8):1819-23
references.pmid: 12918128
references.citation: Zhonghua Yi Xue Za Zhi. 2004 Feb 2;84(3):214-8
references.pmid: 15059537
references.citation: Eur J Cancer. 2004 Mar;40(4):549-58
references.pmid: 14962722
references.citation: Oncol Rep. 2004 Apr;11(4):825-31
references.pmid: 15010880
references.citation: Cancer. 1998 Oct 1;83(7):1328-34
references.pmid: 9762933
references.citation: Int J Mol Med. 2003 Feb;11(2):217-21
references.pmid: 12525881
references.citation: Oncol Rep. 2003 Jul-Aug;10(4):963-6
references.pmid: 12792753
references.citation: J Med Virol. 2004 Feb;72(2):312-9
references.pmid: 14695676
references.citation: Am J Gastroenterol. 2000 Aug;95(8):1939-45
references.pmid: 10950039
references.citation: Pathol Int. 2003 May;53(5):265-9
references.pmid: 12713559
references.citation: N Engl J Med. 2004 Mar 18;350(12):1200-10
references.pmid: 15028824
references.citation: Am J Surg Pathol. 2002 Aug;26(8):989-97
references.pmid: 12170085
references.citation: Hum Pathol. 2004 May;35(5):576-81
references.pmid: 15138932